bioTheranostics : its Breast Cancer IndexSM predicts risk for late recurrence in early stage ER-positive breast cancer patients

December 10, 2010 – bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced new findings from a clinical study evaluating the company’s Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

The company also announced that the Breast Cancer Index is now available to provide quantitative assessment of the risk of distant disease recurrence. The BCI risk assessment is based on data from a recently completed large, randomized, retrospective trial.

“The results presented in San Antonio today become part of a substantial and growing body of data supporting the clinical value of the Breast Cancer Index,” said Richard Ding, chief executive officer of bioTheranostics. “We are pleased to make this valuable test available to oncologists and pathologists in an enhanced format with clinical data specific for late breast cancer recurrence.”...

[...]

...About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community to support targeted disease management. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: Breast Cancer Index, which provides risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer; and the CancerTYPE IDâ test, a cancer classification assay that provides molecular classification of cancers with indeterminate, uncertain, or differential diagnoses to aid in the determination of the tumor site of origin... bioTheranostics' Press Release -

bioMerieux : Collaboration with University of Sunderland in New Research Significantly Improving the Identification of Pseudomonas aeruginosa

April 3, 2008 . A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .

Researchers at the University of Sunderland’s Pharmacy School, Professor Paul Groundwater and Dr. Roz Anderson, in collaboration with Prof. John Perry of Freeman Hospital in Newcastle, Prof. Arthur James of Northumbria University and Sylvain Orenga of bioMérieux have discovered a new technique for the highly specific detection of Pseudomonas aeruginosa, which primarily infects the lungs of patients with cystic fibrosis. It is also a major cause of infection among patients with immune deficiencies, such as patients with AIDS and cancer or those suffering from burns... bioMérieux's Press Release - Communiqué de Presse de BioMérieux -

bioMérieux’s VIDAS® B·R·A·H·M·S PCT® Assay A First Indication for Sepsis Risk Assessment in the ICU

Oct. 18, 2007 - bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® B·R·A·H·M·S PCT®. The test will be used with critically ill patients on their first day of admission to the Intensive Care Unit (ICU) as an aid to assess their risk for progression to severe sepsis and septic shock... bioMérieux's Press Release -

bioMerieux , Diagnosis and Prognosis of Heart Failure

October 1, 2007. bioMérieux, a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics... bioMérieux's Press Release-